AUTHORS
Boyu Hu, MD, Jennifer Seelisch, MD2, Lindsay A. Renfro, PhD3, Adam Duvall, MD, MPH4, Yue Wu, MS5, Steve Yoon-Ho Cho, MD6, Bradford Hoppe, MD, MPH7, Sarah Milgrom, MD8, Raymond Mailhot, MD, MPH9, Andrea C. Lo, MD, MPH10, David Hodgson, MD, MPH11, Lisa G Roth, MD12, Natalie S Grover, MD13, Ann LaCasce, MD, MMSc14, Justine M. Kahn, MD, MS15, Susan Parsons, MD, MRP16, Pamela Hinds, PhD, RN, MSN17, Pamela Allen, MD18, Andrew Evens I, DO,MBA, MSc19, Heiko Schoder, MD20, Sharon M Castellino Jr, MD, MSc21, Kara M Kelly, MD22
AFFILIATIONS
1 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
2 Children's Hospital London Health Sciences Centre, London, Ontario, Canada
3 University of Southern California, Los Angeles, California, United States
4 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
5 University of Florida, Gainesville, Florida, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Children's Hospital Colorado, Aurora, Colorado, United States
9 University of Miami, Miami, Florida, United States
10 BC Cancer, Vancouver, British Columbia, Canada
11 University of Toronto, Toronto, Ontario, Canada
12 NYU Langone Health, New York, New York, United States
13 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 NYP/Columbia University Medical Irving Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
16 Tufts Medical Center, Boston, Massachusetts, United States
17 Children's National Medical Center, Washington, District of Columbia, United States
18 Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
19 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Children's Healthcare of Atlanta, Atlanta, Georgia, United States
22 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Background: Chemotherapy with or without radiotherapy (RT) is currently the standard frontline treatment for early-stage (ES) classic Hodgkin lymphoma (cHL) and has achieved cure rates of >90%. However, adolescent and young adults (ages 15-39) account for ~50% of new cHL diagnoses, necessitating the need to develop novel ES cHL treatments that not only maintain these historically high cure rates, but also aim to minimize the acute and long-term toxicities associated with chemotherapy and RT for these young patients. Recent data from the North American Hodgkin Lymphoma Consortium has demonstrated an impressive 100% 2-year PFS for patients achieving a CR after an initial 2 cycles of ABVD followed by sequential brentuximab vedotin (BV) and nivolumab (BV/Nivo) treatment without the need for consolidative RT (LaCasce AS et al. ASH 2024 Abstract #459). Since these results were reported from a cohort of 45 participants, a larger confirmatory study is needed to validate these results. Therefore, we hypothesized that the incorporation of novel immunotherapy (IO) agents into the frontline setting for ES HL offers new potential therapy options that could reduce patient exposure to chemotherapy and RT but still improve PFS while maintaining overall survival (OS).
Study Design: AHOD2131 (NCT05675410) is a randomized, phase 3 trial for patients ages 5 to 60 years with newly diagnosed, previously untreated, stage I/II cHL, investigating the addition of BV/Nivo compared to standard chemotherapy +/- RT. The primary objective of the study is to compare the PFS of patients treated through a response-adapted, superiority design with either standard or IO (i.e. BV/Nivo) therapies with the key secondary objective of demonstrating non-inferiority of 12-year OS. There are 11 additional secondary and exploratory study aims that focus on patient-reported outcomes (PROs), disease biology and imaging.
Patients are initially stratified based on the European Organisation for Research and Treatment of Cancer (EORTC) criteria for ES HL favorable or unfavorable risk with an additional criterion of mediastinal bulky disease ≥10 cm also considered unfavorable. All patients, regardless of initial risk assessment, receive 2 cycles of ABVD followed by an interim PET2 that is rapidly centrally reviewed. Those patients who are PET2 positive (slow early response [SER]) will undergo separate randomizations as compared to those who are PET2 negative (rapid early response [RER]). The RER participants are randomized to be treated with an additional 2 cycles of ABVD (Arm A) for favorable patients or 4 cycles of AVD (Arm E) for unfavorable patients versus 4 cycles of BV/Nivo (Arms B and F); no RER participants (estimated to be ~85% of the study population) receive consolidative RT. SER participants will be randomized to receive either 2 additional cycles of investigator’s choice of escalated BEACOPP/BPDac (Arms C and G) or BV/Nivo x4 cycles (Arms D and H) followed by involved site RT.
Methods: AHOD2131 is a collaborative study developed between pediatric and adult oncology members of the National Cancer Institute’s National Clinical Trial Network (NCTN), aiming to harmonize IO-based treatment approaches for ES cHL. Study champions from each North American (NA) cooperative group (Children’s Oncology Group [COG], SWOG, ECOG-ACRIN, Alliance, NRG) and experts in imaging, radiation oncology, lymphoma biology and PROs were included in the development and execution of AHOD2131. AHOD2131 was activated in April 2023 with a target enrollment of 1875 patients over 5 years. The study is designed to demonstrate superiority in PFS with an improvement of 3-year PFS from 89.9% to 93.7% (84.5% power to detect a hazard ratio of 0.61) for RER participants and from 67.5% to 79.6% (80% power to detect a hazard ratio of 0.58) for SER.
As of 13 July 2026, 395 NA sites have activated the study and 926 participants have enrolled. Out of the patients enrolled, 49% are <18 years old and 66% are ES unfavorable risk.
Conclusion: This COG-led pan-NCTN trial will be the largest study for ES cHL in the history of the NA cooperative groups and the first to enroll both pediatric and adult patients. AHOD2131 strengthens the effort between NA cooperative groups to conduct collaborative clinical trials and aims to harmonize an improved standard of care for ES cHL across the age continuum.
DISCLOSURES
Boyu Hu, MD: Genentech - Research Funding; Newave - Research Funding; Caribou Biosciences - Research Funding; Morphosys AG - Research Funding; Lyell Immunopharma - Research Funding; Incyte Corporation - Research Funding; AstraZeneca - Research Funding; Artiva Biotherapeutics - Research Funding; Genentech - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)